

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) - Market Insights, Epidemiology and Market Forecast 2028

<https://marketpublishers.com/r/N3F29114A2EEN.html>

Date: August 2019

Pages: 120

Price: US\$ 6,250.00 (Single User License)

ID: N3F29114A2EEN

Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's "Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) - Market Insights, Epidemiology and Market Forecast – 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) epidemiology. It highlights the existing treatment patterns, potential upcoming Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.

Markets Covered

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2017-2028

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Understanding and Treatment Algorithm

The Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) market report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in the US, Europe, and Japan are also provided in the report.

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Epidemiology

This section provide the insights about historical and current Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Product Profiles & Analysis

This part of the report encloses the detailed analysis of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Market Outlook

The Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight. Nonsense Mutation Duchenne Muscular

Dystrophy (nmDMD) Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Report Insights

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Patient Population

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Therapeutic Approaches

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Pipeline Analysis

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Market Size and Trends

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Market Opportunities

Impact of upcoming Therapies in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Report Key Strengths

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 10 Year Forecast

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) 7MM Coverage

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Epidemiology Segmentation

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Drugs Uptake

Highly Analyzed Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Market

Key Cross Competition

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Report Assessment

Current Treatment Practices in Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Unmet Needs

Detailed Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Pipeline Product Profiles

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Market Attractiveness

Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Market Drivers and Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) market

Organize sales and marketing efforts by identifying the best opportunities for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) market

To understand the future market competition in the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) market.

Contents

1. REPORT INTRODUCTION

2. NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD) MARKET OVERVIEW AT A GLANCE

2.1. Market Share Distribution of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 2017

2.2. Market Share Distribution of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 2028

3. DISEASE BACKGROUND AND OVERVIEW: NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD)

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM

4.3. Total Prevalent Patient Population of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM – By Countries

5. EPIDEMIOLOGY OF NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD) BY COUNTRIES

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.1.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular

Dystrophy (nmDMD) *Indication Specific

5.1.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *Indication Specific

5.1.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.1.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.4.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.4.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.4.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.4.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.5. France

5.5.1. Assumptions and Rationale

5.5.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.5.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.5.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.5.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.5.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.6. Italy

5.6.1. Assumptions and Rationale

5.6.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.6.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.6.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.6.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.6.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.7. Spain

5.7.1. Assumptions and Rationale

5.7.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.7.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.7.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.7.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.7.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.8. United Kingdom

5.8.1. Assumptions and Rationale

5.8.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.8.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.8.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.8.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.8.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.9. Japan

5.9.1. Assumptions and Rationale

5.9.2. Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

5.9.3. Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.9.4. Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) *

5.9.5. Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy

(nmDMD)

5.9.6. Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy

(nmDMD)

6. CURRENT TREATMENT & MEDICAL PRACTICES

6.1. Treatment Algorithm

6.2. Treatment Guidelines

7. UNMET NEEDS OF THE NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD)

8. MARKETED THERAPIES

8.1. Drug A: Company

8.1.1. Drug Description

8.1.2. Mechanism of Action

8.1.3. Regulatory Milestones

8.1.4. Advantages & Disadvantages

8.1.5. Product Profile

8.2. Drug B: Company

8.2.1. Drug Description

8.2.2. Mechanism of Action

8.2.3. Regulatory Milestones

8.2.4. Advantages & Disadvantages

8.2.5. Product Profile

9. PIPELINE THERAPIES – AT A GLANCE

10. KEY CROSS COMPETITION

11. EMERGING THERAPIES FOR NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD)

11.1. Drug C: Company

11.1.1. Drug Description

11.1.2. Clinical Trials Details

11.1.3. Safety and Efficacy Profile

11.1.4. Advantages & Disadvantages

- 11.1.5. Pipeline Development Activities
- 11.1.6. Product Profile
- 11.2. Drug D: Company
 - 11.2.1. Drug Description
 - 11.2.2. Clinical Trials Details
 - 11.2.3. Safety and Efficacy Profile
 - 11.2.4. Advantages & Disadvantages
 - 11.2.5. Pipeline Development Activities
 - 11.2.6. Product Profile

12. NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD) : 7MM MARKET ANALYSIS

- 12.1. 7MM Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
- 12.2. 7MM Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
- 12.3. 7MM Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products

13. NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD) : COUNTRY-WISE MARKET ANALYSIS

- 13.1. United States
 - 13.1.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States
 - 13.1.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States
 - 13.1.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in United States
 - 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
- 13.2. EU-5
 - 13.2.1. Germany
 - 13.2.1.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany
 - 13.2.1.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany
 - 13.2.1.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in Germany
 - 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.2. France

13.2.2.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France

13.2.2.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France

13.2.2.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in France

13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.3. Italy

13.2.3.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy

13.2.3.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy

13.2.3.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.4. Spain

13.2.4.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain

13.2.4.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain

13.2.4.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.5. United Kingdom

13.2.5.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United Kingdom

13.2.5.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan

13.3.2. Percentage Share of drugs marketed for Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan

13.3.3. Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. MARKET DRIVERS

15. MARKET BARRIERS

16. APPENDIX

17. REPORT METHODOLOGY

17.1. Sources

18. DELVEINSIGHT CAPABILITIES

19. DISCLAIMER

20. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1: Total Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM

Table 2: Total Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Table 4: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Table 5: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Table 6: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Table 7: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Table 8: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Table 9: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Table 10: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Table 11: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Table 12: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Table 13: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Table 14: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Table 15: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Table 16: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Table 17: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Table 18: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular

Dystrophy (nmDMD) in Italy (2017-2028)

Table 19: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028)

Table 20: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028)

Table 21: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028)

Table 22: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028)

Table 23: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Table 24: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Table 25: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Table 26: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Table 27: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Table 28: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Table 29: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Table 30: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Table 31: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Table 32: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Table 33: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Table 34: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Table 35: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Table 36: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Table 37: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Table 42:7MM- Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 43:7MM- Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 44: United States-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Table 45: United States-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 46: United States-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 47: Germany-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Table 48: Germany-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 49: Germany-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 50: France-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Table 51: France-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 52: France-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 53: Italy-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Table 54: Italy-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 55: Italy-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 56: Spain-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Table 57: Spain-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 58: Spain-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 59:UK-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Table 60:UK-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 61:UK-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 62: Japan-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Table 63: Japan-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Table 64: Japan-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

List Of Figures

LIST OF FIGURES

Figure 1: Total Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Figure 4: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Figure 5: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Figure 6: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Figure 7: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in United States (2017-2028)

Figure 8: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Figure 9: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Figure 10: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Figure 11: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Figure 12: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Germany (2017-2028)

Figure 13: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Figure 14: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Figure 15: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Figure 16: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Figure 17: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in France (2017-2028)

Figure 18: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular

Dystrophy (nmDMD) in Italy (2017-2028)

Figure 19: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028)

Figure 20: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028)

Figure 21: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028)

Figure 22: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Italy (2017-2028)

Figure 23: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Figure 24: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Figure 25: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Figure 26: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Figure 27: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Spain (2017-2028)

Figure 28: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Figure 29: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Figure 30: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Figure 31: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Figure 32: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in UK (2017-2028)

Figure 33: Prevalent/Incident Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Figure 34: Sub-Type Specific cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Figure 35: Sex- Specific Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Figure 36: Diagnosed Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Figure 37: Treatable Cases of the Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in Japan (2017-2028)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41: 7MM- Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Figure 42: 7MM- Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 43: 7MM- Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 44: United States-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Figure 45: United States-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 46: United States-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 47: Germany-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Figure 48: Germany-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 49: Germany-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 50: France-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Figure 51: France-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 52: France-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 53: Italy-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Figure 54: Italy-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 55: Italy-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 56: Spain-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Figure 57: Spain-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 58: Spain-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 59:UK-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Figure 60:UK-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 61:UK-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 62: Japan-Market Size of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) in USD MM (2017-2028)

Figure 63: Japan-Market Share Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

Figure 64: Japan-Market Sales of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) by Therapies in USD MM (2017-2028)

I would like to order

Product name: Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) - Market Insights, Epidemiology and Market Forecast 2028

Product link: <https://marketpublishers.com/r/N3F29114A2EEN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N3F29114A2EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

